Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.72 |
| ▸ | HPGD | P15428 | 5/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.72 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.72 |
| ▸ | TNF | P01375 | 2/20 | 0.51 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.51 |
| ▸ | PSD | A5PKW4 | 6/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3561223 | 0.86 | KDM4E (0.74) | KDM4EALDH1A1HPGDCYP1A2CYP2C9 | |
| SCHEMBL3562827 | 0.86 | KDM4E (0.74) | KDM4EALDH1A1HPGDCYP1A2CYP2C9 | |
| SCHEMBL3559155 | 0.85 | HPGD (0.64) | KDM4EALDH1A1HPGDCYP1A2CYP2C9 | |
| SCHEMBL19196267 | 0.84 | KDM4E (0.72) | KDM4EALDH1A1HPGDCYP1A2CYP2C9 | |
| SCHEMBL3563063 | 0.84 | KDM4E (0.71) | KDM4EALDH1A1HPGDCYP1A2CYP2C9 | |
| SCHEMBL3558552 | 0.83 | KDM4E (0.66) | KDM4EALDH1A1HPGDCYP1A2CYP2C9 | |
| SCHEMBL3562302 | 0.81 | ALDH1A1 (0.59) | KDM4EALDH1A1HPGDCYP1A2CYP2C9 | |
| SCHEMBL3565865 | 0.81 | TNF (0.57) | KDM4EALDH1A1HPGDCYP1A2CYP2C9 | |
| SCHEMBL2402085 | 0.79 | KDM4E (0.64) | KDM4EALDH1A1HPGDCYP1A2CYP2C9 | |
| SCHEMBL3556095 | 0.78 | HPGD (0.62) | KDM4EALDH1A1HPGDCYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2001849-B1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2014-11-26 | — | — | EP | disclosed |
| EP-2468727-A1 | Pyridine and pyrimidine derivatives as MGLUR2 antagonists | F. Hoffmann-La Roche AG (CH) | 2012-06-27 | — | — | EP | disclosed |
| CN-102516161-A | Pyridine and pyrimidine derivatives as mglur2 antagonists | HOFFMANN LA ROCHE | 2012-06-27 | — | — | CN | disclosed |
| US-8183262-B2 | Central nervous system disorders; metabotropic glutamate receptors (mGluR); 2-(4-Pyridin-3-yl-imidazol-1-yl)-4-trifluoromethyl-6-(4-trifluoromethyl-phenyl)-pyrimidine | HOFFMANN-LA ROCHE INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-7642264-B2 | Phenyl-substituted pyrimidine derivatives as mGluR antagonists | HOFFMAN-LA ROCHE INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-20090318474-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR 2 ANTAGONISTS | GATTI MCARTHUR SILVIA | 2009-12-24 | — | — | US | disclosed |
| CN-101415681-A | Pyridine and pyrimidine derivatives as mGluR2 antagonists | HOFFMANN LA ROCHE (CH) | 2009-04-22 | — | — | CN | disclosed |
| EP-2001849-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2008-12-17 | — | — | EP | disclosed |
| US-20070232583-A1 | Pyridine and pyrimidine derivatives as mGIuR2 antagonists | HOFFMANN-LA ROCHE INC. | 2007-10-04 | — | — | US | disclosed |
| WO-2007110337-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232583-A1 | Pyridine and pyrimidine derivatives as mGIuR2 antagonists | P2RX2, P2RY2, P2RX1 | KDM4E 2568/4885ALDH1A1 1138/4885HPGD 1536/4885 |
| US-20090318474-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR 2 ANTAGONISTS | GRM2, GRM1, GRM3 | KDM4E 1276/4885ALDH1A1 3286/4885HPGD 1468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.